PGD Compatibility Test

InformativeHelp to determine the risk of having a child with Inherited genetic disease and/or hereditary cancer

Reliable Prevent the transmission of genetic disease and/or hereditary cancer to their baby by analyzing their embryos during an IVF cycle for the specific mutations that they carry

AccurateState-of-the-art clinically validated NGS technology to ensure precise results.

 

In terms of trying to start a family, there is a 50% chance that your genetic mutation could be passed onto your children. The PGD Compatibility Test is an important genetic test when planning a family, because it helps to determine the risk of having a child with Inherited Genetic Disease and/or Hereditary Cancer.

  • PGD-Carrier Screen Compatibility Test

Couple considering having a baby may wish to have their DNA tested to screen for mutations in certain genes that are associated with common and rare inherited diseases.  This allows them to determine the possibility that they will pass on genes that may cause genetic diseases in their future children. In the occasion of the couple receive results indicating they are carriers for mutations in the same gene, GeneseqDx can further aid their family planning process by performing the PGD-Carrier Screen Compatibility Test. This test can prevent the transmission of disease to their baby by analyzing their embryos during an IVF cycle for the specific mutations that they carry.

 

  • PGD-Hereditary Cancer Compatibility Test

Similar to Carrier Screening, a couple considering having a baby may wish to have their DNA tested to screen for mutations in certain genes that are associated with common and rare hereditary cancers.  This allows them to determine the possibility that they will pass on genes that may cause cancer in their future children. When a couple receives results that include a cancer-causing mutation, they can choose to use the PGD-Hereditary Cancer Compatibility Test  with GeneseqDx to detect this specific mutation in their embryos during an IVF cycle.